培美曲塞二钠一线治疗老年Ⅳ期肺腺癌48例临床分析 |
| |
引用本文: | 许建伟,张海兵,郑少俊,茹利新,纪鹏天,俞根华.培美曲塞二钠一线治疗老年Ⅳ期肺腺癌48例临床分析[J].浙江中医药大学学报,2014(4):414-418. |
| |
作者姓名: | 许建伟 张海兵 郑少俊 茹利新 纪鹏天 俞根华 |
| |
作者单位: | 湖州市中心医院介入放疗科 浙江,湖州313000 |
| |
基金项目: | 浙江省湖州市科技局(2009YS03);浙江省湖州市科技局(2013GYB03) |
| |
摘 要: | 目的]观察培美曲塞(pemetrexed,PEM)单药一线治疗老年晚期肺腺癌的疗效及毒性反应。方法]经细胞学或组织学确诊的48例老年晚期肺腺癌非小细胞肺癌(non small cell lung cancer,NSCLC)患者,均接受单药PEM化疗,培美曲塞二钠以500 mg/m2,第1d静脉滴注,21d为1周期,每例患者至少行2周期化疗;观察临床有效率(RR)、疾病控制率、疾病进展时间(TTP)、生活质量及化疗相关毒副反应。结果]CR 1例,PR 20例,SD 15例,PD 12例,RR43.8%,临床获益率(CBR)75.0%,平均疾病进展时间TTP 11.2月;生活质量改善50%,稳定33.3%,有效率达83.3%;化疗相关毒副反应较轻,主要为血液学毒性(骨髓抑制)和消化道反应,多为Ⅰ--Ⅱ级,无Ⅳ度毒副反应发生。结论]单药PEM一线治疗老年晚期肺腺癌具有较好的疗效,而毒性反应较轻。
|
关 键 词: | PEM 老年 晚期肺腺癌 NSCLC 化疗 |
Clinical Analysis of Pemetrexed Alone as First-line Drug in the Treatment of Elderly Patients 48 Cases with Advanced Lung Adenocarcinoma |
| |
Institution: | Xu Jianwei, Zhang Haibing, Zheng Shaojun, et al( Department of Interventional Radioology and Radiation Oncology, Huzhou Central Hospital, Zhejiang Provirtce313000, China ) |
| |
Abstract: | Objective] To observe the efficacy and toxicity of pemetrexed alone as first-line drug in the treatment of the elderly patients with advanced lung adenocarcinoma.Methods]48 elderly patients with advanced lung adenocarcinoma confirmed by pathology or cytology were treated with pemetrexed 500 mg/m2 through intravenous drip.3 weeks was a cycle and each patient was given at least 2 cycles of chemotherapy.Results]There was only 1 case of complete remission(CR),20 cases of partial remission(PR),15 cases of stable disease(SD) and 12 cases of progressive disease(PD) after the treatment .The overal response rate was 43.8% and the clinical beneficial rate was 75.0%.The median time to progress(TTP) was 11.2 months. The improving of QOL was remarkable. The major adverse reactions were myelosuppression and gastrointestinal reactions .There was no chemotherapy-related death occurred. Conclusion] Pemetrexed alone in the treatment of elderly patients with advanced lung adenocarcinoma has a better efficacy with lower toxicity and good tolerance. |
| |
Keywords: | PEM NSCLC PEM elderly advanced lung adenocarcinoma NSCLC chemotherapy |
本文献已被 CNKI 维普 等数据库收录! |
|